Scientific deep-dive

Compounded Semaglutide vs Wegovy: Bioequivalence Evidence Review

No FDA bioequivalence study exists between compounded semaglutide and Wegovy. The 2022-2025 shortage carveout closed February 21, 2025, and the FDA is now issuing warning letters to online sellers. What the rules actually say.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
10 min read·17 citations

The honest answer: Compounded semaglutide is not FDA-tested for bioequivalence to Wegovy. No such study has ever been required, run, or published. The 2022 to early-2025 FDA shortage listing temporarily permitted §503A and §503B compounding; that window closed in February 2025, and the agency is now actively issuing warning letters.[1]

Compare vetted semaglutide providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

No insurance needed · HSA/FSA eligible · vetted by our editors

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Starting price: $59/mo (+ required membership)

Get started →Read review Collective →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Starting price: $79/mo (starting price)

Get started →Read review CoreAge Rx →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Starting price: $79/mo (sale price)

Get started →Read review Embody →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Starting price: $129/mo (starting dose)

Get started →Read review Gala →
8.3

Found

Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s

Starting price: $169/mo (12-month plan rate)

Get started →Read review Found →

At a glance

  • Zero bioequivalence trials comparing any compounded semaglutide preparation to FDA-approved Wegovy exist in the public literature.[2]
  • The FDA-approved Wegovy formulation is the semaglutide base peptide (molecular weight 4113.58 g/mol) in a sterile aqueous solution.[3] The FDA says some compounded semaglutide products may be salt forms (semaglutide sodium, semaglutide acetate), which are different active ingredients than the ones in the approved drugs.[5]
  • The §503A and §503B compounding carveouts never required bioequivalence testing. They were designed for patient-specific preparations, not for parallel mass markets.[1]
  • The FDA declared the semaglutide-injection shortage resolved on February 21, 2025, ending the shortage-list exemption that had permitted scaled compounding. A federal district court upheld that decision, and the U.S. Court of Appeals for the Fifth Circuit affirmed on August 27, 2026.[11][14]
  • The FDA's GLP-1 safety page states that compounded drugs are not FDA approved, meaning “the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.” As of May 31, 2026, the agency had received 990 adverse-event reports tied to compounded semaglutide.[5]
  • In 2025 to 2026, the FDA issued warning letters to online sellers of semaglutide and related GLP-1 products, and on March 3, 2026 announced 30 more letters to telehealth companies for false or misleading claims about compounded GLP-1s.[6][7][13]

What “bioequivalence” actually means at FDA

The FDA's definition of bioequivalence is narrow and operational. Two drug products are bioequivalent when “the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action” shows no significant difference at the same molar dose under similar conditions.[17] In practice that means healthy-volunteer pharmacokinetic studies measuring the plasma area under the curve (AUC) and peak concentration (Cmax), with the generic product's 90% confidence interval required to fall within 80–125% of the reference product on both metrics.

Bioequivalence is the regulatory mechanism by which generic drugs get approved as substitutable for brand-name originators through the Abbreviated New Drug Application (ANDA) pathway. Compounded products are not generic drugs, do not file ANDAs, and by definition have not undergone bioequivalence testing. This is not a loophole; it is the explicit structure of the compounding statute.[1] Tirzepatide is in the same position: the bioequivalence picture for Zepbound and its compounded versions is just as empty.

Anyone marketing a compounded GLP-1 as “bioequivalent to Wegovy” is using the word colloquially (“basically the same”) rather than in the regulatory sense, and the distinction matters because no compounded product on the U.S. market carries the data that would support the regulatory claim.

Wegovy's FDA-approved formulation (DailyMed verbatim)

The current Wegovy prescribing information on DailyMed describes the active ingredient verbatim as:

“WEGOVY contains semaglutide, a human GLP-1 receptor agonist (or GLP-1 analog). The peptide backbone is produced by yeast fermentation. The main protraction mechanism of semaglutide is albumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid. … The molecular formula is C187H291N45O59 and the molecular weight is 4113.58 g/mol.”[3]

The §3 Dosage Forms and Strengths section lists single-dose pens and syringes in escalation strengths of 0.25, 0.5, 1, 1.7, and 2.4 mg, a 7.2 mg WEGOVY HD single-dose pen, a 9.6 mg/3 mL WEGOVY FlexTouch pen that delivers four 2.4 mg doses, and tablet strengths of 1.5, 4, 9, and 25 mg. The injection is described as a “clear, colorless solution,” and the active ingredient throughout is identified as semaglutide (no salt qualifier).[3]

This matters because the molecular weight (4113.58 g/mol) is the base-form weight. Semaglutide sodium and semaglutide acetate have different molecular weights and have not been evaluated in any pivotal trial submitted to the FDA. The STEP-1 efficacy data that underpinned Wegovy's 2021 weight-loss approval used the base form exclusively.[9]

Why the §503A shortage window enabled the compounded market

Under §503A of the Federal Food, Drug, and Cosmetic Act, a traditional state-licensed compounding pharmacy cannot compound a drug that is “essentially a copy” of a commercially available FDA-approved product. That rule exists to stop compounders from undercutting brand manufacturers on patented medications. The statutory exception is §506E (codified at 21 U.S.C. §356e), which directs the FDA to maintain a public drug-shortage list. When a drug is on that list, the “essentially a copy” prohibition is temporarily lifted.[1]

The FDA added Wegovy to the drug-shortage list on March 31, 2022, and Ozempic on August 23, 2022, as Novo Nordisk struggled to keep up with demand.[14] That listing — which persisted until February 2025 — was the legal hook that made it possible for §503A pharmacies and §503B outsourcing facilities, plus the telehealth platforms that contract with them, to compound and dispense semaglutide at scale. The §506E carveout was clearly intended to keep hospital infusions and oncology drugs flowing during supply disruptions, not to stand up a parallel direct-to-consumer retail market for weight-loss injections, but the statute does not distinguish.[4]

On February 21, 2025, the FDA officially resolved the semaglutide-injection shortage and posted the revised status to its public shortages database. The FDA then gave compounders a wind-down period: for §503A pharmacies, until April 22, 2025 or a court ruling on a pending preliminary-injunction motion, whichever came later; for §503B outsourcing facilities, until May 22, 2025. The court denied that motion on April 24, 2025, which ended the §503A enforcement discretion, and the §503B window closed on May 22, 2025.[4][11]

The compounders' legal challenge has since failed at every level. In Outsourcing Facilities Association v. FDA, the district court entered judgment for the FDA, and on August 27, 2026 the Fifth Circuit affirmed. It held that any error in skipping notice-and-comment procedures was harmless and that the FDA's decision to remove semaglutide from the shortage list was not arbitrary or capricious.[14] In an April 1, 2026 update, the FDA noted that semaglutide is on neither the §503B bulks list nor the drug shortage list. It also said a compounded product that adds an ingredient such as vitamin B12 may still be treated as “essentially a copy” of approved products when the strengths are within 10% of each other. The agency said it does not intend to act against a §503A compounder that fills four or fewer prescriptions of such a product in a calendar month.[11]

What the FDA's GLP-1 safety page warns about compounded products

The FDA's dedicated patient-and-provider page on FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss is unambiguous. It states that compounded drugs are not FDA approved, and:

“This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.”[5]

The same page specifies that newer GLP-1s including retatrutide and cagrilintide “cannot be used in compounding under federal law” because they are not yet approved at all, separating those investigational molecules from the semaglutide-specific shortage carveout that briefly applied.[5]

The page also flags specific recurring problems with compounded GLP-1s. The first is dosing errors: patients measuring and self-injecting the wrong dose, clinicians miscalculating doses, and doses or titration schedules beyond the FDA-approved label, some leading to hospitalization. The second is salt forms: semaglutide sodium and semaglutide acetate are “different active ingredients” than the approved drugs, and the agency says it is not aware of any lawful basis for using them in compounding. The page also warns about multi-dose vials (discard 28 days after first use), products shipped warm, and fraudulent products labeled with pharmacies that do not exist or did not make them.[5]

The page reports that, as of May 31, 2026, the FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. It cautions that the true numbers are likely higher, because §503A pharmacies are not required to report adverse events to the FDA. At the border, the agency has set up a “green list” import alert (66-80) to stop GLP-1 active ingredients with potential quality concerns from entering the U.S. supply chain.[5]

FDA enforcement: warning letters to compounders 2025 to 2026

Since the shortage resolution, the FDA Center for Drug Evaluation and Research (CDER) has issued multiple warning letters to online sellers of GLP-1 products. Two September 9, 2025 letters to GLP-1 Solution[6] and ASN-LABS[7] found their retatrutide products to be unapproved and misbranded drugs, and their claims about compounded semaglutide false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Two March 31, 2026 letters went to Prime Sciences[8] and Mile High Compounds LLC[10]. Both sold GLP-1 peptides, including semaglutide, labeled “for research purposes” or “not for human consumption” while promoting them for human weight loss, and the FDA classified the products as unapproved new drugs.

Enforcement has also moved up the supply chain and into advertising. On February 6, 2026, the FDA announced it intends to restrict GLP-1 active ingredients used in mass-marketed, non-approved compounded drugs, naming Hims & Hers among the companies involved. The agency warned that companies may not claim compounded products are generic versions of, the same as, or made with the same active ingredient as FDA-approved drugs. It said failure to comply could lead to seizure or injunction.[12] On March 3, 2026, the FDA issued 30 warning letters to telehealth companies. The main violations were claims implying sameness with FDA-approved products and branding compounded drugs with the telehealth company's own name, which hides who actually compounded them.[13] The ongoing live dataset of every FDA warning letter we have identified against GLP-1 compounders is at FDA warning letters to compounded GLP-1 telehealth providers.

Salt forms, potency variability, and sterility risk

How these products are marketed matters too. A 2025 analysis of the direct-to-consumer compounded GLP-1 market in Colorado found 93 business websites advertising compounded GLP-1s. Of these, 41 referred to FDA approval when describing compounded products and 5 called them “generic.” The authors found no business openly advertising a salt form, and several websites said their products did not contain one.[2]

Even when the molecule is the base peptide, compounded preparations are not required to meet the same potency-band and stability requirements as FDA-approved products. United States Pharmacopeia (USP) chapters governing sterile compounding (notably USP <797>) require sterility and endotoxin testing for finished sterile preparations, but §503A pharmacies are not required to run bioavailability studies, head-to-head clinical comparisons, or long-term stability programs comparable to a brand-name manufacturer. The §503B outsourcing-facility framework layers cGMP requirements on top of USP, narrowing but not eliminating the gap.[5]

Laboratory data comparing compounded and branded semaglutide are now starting to appear, though the main study comes from the brand manufacturer. In a 2026 analysis in Pharmaceutical Research, Novo Nordisk scientists tested follow-on and compounded semaglutide and liraglutide products. They found impurity profiles that differed from the originators, with amino-acid deletions or additions and unidentified impurities. When the products were exposed to light, compounded semaglutide differed significantly from the originator in strength, total impurities, and high-molecular-weight protein levels. In a cell-based assay, some of the impurities showed potential to trigger an immune response. All of the authors were Novo Nordisk employees, shareholders, or former employees, and the study measured laboratory markers, not clinical outcomes in patients.[15] Separately, a secret-shopper study done from August to October 2025, after the shortage ended, identified 75 weight-loss clinics and medical spas in West Virginia and Oklahoma that were still selling compounded GLP-1s. Of these, 42 (56%) reported offering products combined with B vitamins and 7 offered oral formulations. Among 21 supplying facilities with licensing data, 4 were not licensed for sterile compounding.[16]

For context on what FDA-approved semaglutide actually delivers in a controlled trial, the STEP-1 pivotal study (Wilding et al., 2021, NEJM) randomized 1,961 adults with obesity to once-weekly semaglutide 2.4 mg versus placebo and showed a mean placebo-adjusted body-weight change of -12.4 percentage points at week 68.[9] That magnitude reflects the FDA-approved formulation, FDA-approved dosing, and FDA-required quality controls. None of those parameters automatically transfer to a compounded preparation.

If you're on compounded semaglutide today, what to do

For patients currently using a compounded preparation, the practical checklist is short:

  1. Identify the source pharmacy in writing. The telehealth provider should name a specific 503A or 503B facility. “Our network of partner pharmacies” is not an answer.
  2. Ask which salt form is used. Semaglutide base is the form in Wegovy. Sodium or acetate salts are the forms the FDA has flagged.
  3. Request a certificate of analysis for the lot you receive, documenting identity, potency, and sterility.
  4. Verify dosing in milligrams, not units or milliliters. The FDA has received adverse-event reports, some requiring hospitalization, linked to patients measuring the wrong dose of compounded semaglutide and to clinicians miscalculating doses.[5]
  5. Discuss transition to an FDA-approved product with a clinician. Novo Nordisk's direct-pay channels and FDA-approved alternative oral GLP-1 options may now be price-competitive with what the compounded semaglutide providers we track charge.

Practical takeaway

Compounded semaglutide is not FDA-bioequivalent to Wegovy, has never been required to be, and the statutory window that briefly legalized its mass-market distribution closed on February 21, 2025. The molecule may or may not be the same active ingredient depending on which salt form a particular pharmacy sourced. The product may or may not meet the potency it claims depending on which pharmacy compounded it. Federal courts, including the Fifth Circuit in August 2026, have upheld the FDA's decision to end the shortage. The agency is enforcing against online sellers, telehealth marketers, and suppliers of GLP-1 active ingredients, and is unlikely to reopen the shortage pathway unless supply is disrupted again.

For background on the operational details — what 503A and 503B pharmacies actually test, salt-form chemistry, and the PCAB accreditation framework — see Compounded semaglutide bioequivalence: what 503A pharmacies actually have to test. For the live FDA enforcement dataset, see FDA warning letters to compounded GLP-1 telehealth providers.

Frequently Asked Questions

No. There is no FDA bioequivalence study comparing any compounded semaglutide preparation to Wegovy. Compounded products do not go through the Abbreviated New Drug Application (ANDA) pathway that would require a bioequivalence package, and the §503A and §503B compounding carveouts have never required one.
The legal landscape narrowed sharply on February 21, 2025, when the FDA officially resolved the semaglutide-injection shortage and removed it from the drug-shortage list. The compounders' court challenge failed, and on August 27, 2026 the Fifth Circuit affirmed the FDA's decision. §503A pharmacies can still compound for an individual patient when a prescriber documents that a change makes a significant difference for that patient (for example, an allergy to an inactive ingredient in the brand product). Routine copies of the FDA-approved product are not protected, and the FDA has said that adding an ingredient such as vitamin B12 does not automatically avoid that rule. The FDA is issuing warning letters to online sellers and telehealth marketers.
Per the current DailyMed prescribing information, Wegovy contains semaglutide as the base peptide (molecular formula C187H291N45O59, molecular weight 4113.58 g/mol). The injection is described as a clear, colorless aqueous solution in single-dose pens and syringes and a multi-dose FlexTouch pen, and Wegovy is also approved as a once-daily tablet. There is no salt-form qualifier; the FDA approval is specifically for the base peptide.
The FDA says it is aware that some semaglutide sold by compounders may be a salt form, such as semaglutide sodium or semaglutide acetate. It says these are different active ingredients than the semaglutide in the approved drugs, that it has no information on whether they have the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for using them in compounding. No FDA-approved product uses a salt form.
The FDA officially resolved the semaglutide-injection shortage on February 21, 2025 and posted the revised status to its public drug-shortages database. Enforcement discretion for §503A pharmacies ended when a federal court denied the compounders' preliminary-injunction request on April 24, 2025, and the window for §503B outsourcing facilities ended on May 22, 2025.
Since the shortage resolution, the FDA Center for Drug Evaluation and Research (CDER) has issued warning letters to online GLP-1 sellers, including GLP-1 Solution and ASN-LABS (September 2025, which cited false or misleading compounded-semaglutide claims and unapproved retatrutide) and Prime Sciences and Mile High Compounds LLC (March 2026, for selling GLP-1 peptides labeled 'for research' as unapproved new drugs). In February 2026 the FDA announced plans to restrict GLP-1 active ingredients used in mass-marketed compounded drugs. On March 3, 2026 it issued 30 warning letters to telehealth companies over claims that compounded GLP-1s are the same as FDA-approved drugs.
Officially, the FDA treats compounded drugs as unapproved products, and none of them goes through an FDA review of safety, effectiveness, or quality on the way to market. As of May 31, 2026, the FDA had received 990 adverse-event reports tied to compounded semaglutide. Documented risks include dosing errors (patients measuring the wrong dose, clinicians miscalculating doses, and doses beyond the approved label), salt forms the FDA says have no lawful basis in compounding, fraudulent products with fake pharmacy labels, and contamination or potency variability. Patients on compounded preparations should verify the source pharmacy, the salt form, and request a certificate of analysis on the dispensed lot.
Ask the telehealth provider to identify the source pharmacy in writing (a specific 503A or 503B name, not 'our network'). Ask which salt form is used. Request a certificate of analysis for the dispensed lot documenting identity, potency, and sterility. Verify the dose in milligrams (not in units or milliliters). Discuss with a clinician whether an FDA-approved product such as Wegovy is now accessible at a comparable cost.
The STEP-1 trial (Wilding et al., 2021, NEJM) that produced the -12.4 percentage-point placebo-adjusted weight loss at week 68 used the FDA-approved semaglutide base peptide at the FDA-approved 2.4 mg weekly dose with FDA-required quality controls. None of those parameters automatically transfer to a compounded preparation made from a different salt form or by a pharmacy without bioavailability data.
Our editorial team maintains a live dataset of every FDA warning letter we have identified that targets a compounded GLP-1 telehealth provider, compounding pharmacy, or related weight-loss business. See /research/fda-warning-letters-glp1 for the current list, violation patterns, and issuing offices.

References

  1. 1.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  2. 2.DiStefano MJ, et al. Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado. J Pharm Policy Pract. 2025. PMID: 39776466.
  3. 3.Novo Nordisk Pharmaceutical Industries, LP. WEGOVY (semaglutide) injection, solution / tablet — Prescribing Information (DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b). DailyMed (NIH NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  4. 4.U.S. Food and Drug Administration. FDA Drug Shortages — Semaglutide Injection (status: Resolved, February 21, 2025). FDA Drug Shortages Database. 2025. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=r
  5. 5.U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. 6.U.S. Food and Drug Administration (CDER). Warning Letter — GLP-1 Solution (MARCS-CMS 715883), September 9, 2025. FDA Inspections, Compliance, Enforcement and Criminal Investigations. 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025
  7. 7.U.S. Food and Drug Administration (CDER). Warning Letter — ASN-LABS (MARCS-CMS 716459), September 9, 2025. FDA Inspections, Compliance, Enforcement and Criminal Investigations. 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asn-labs-716459-09092025
  8. 8.U.S. Food and Drug Administration (CDER). Warning Letter — Prime Sciences (MARCS-CMS 721805), March 31, 2026. FDA Inspections, Compliance, Enforcement and Criminal Investigations. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026
  9. 9.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021. PMID: 33567185.
  10. 10.U.S. Food and Drug Administration (CDER). Warning Letter — Mile High Compounds LLC (MARCS-CMS 721600), March 31, 2026. FDA Inspections, Compliance, Enforcement and Criminal Investigations. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mile-high-compounds-llc-721600-03312026
  11. 11.U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026). FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  12. 12.U.S. Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs (statement, February 6, 2026). FDA Press Announcements. 2026. https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
  13. 13.U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (March 3, 2026). FDA Press Announcements. 2026. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
  14. 14.U.S. Court of Appeals for the Fifth Circuit. Outsourcing Facilities Association v. Food & Drug Administration, No. 25-10758 (per curiam, unpublished; filed August 27, 2026, revised September 1, 2026). U.S. Court of Appeals for the Fifth Circuit. 2026. https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
  15. 15.Kopp KL, Lamberth K, Schelde O, et al. Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists. Pharm Res. 2026. PMID: 42533250.
  16. 16.DiStefano MJ, Tilley A, Paratane D, et al. Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand. JAMA Health Forum. 2026. PMID: 42467450.
  17. 17.U.S. Code of Federal Regulations. 21 CFR 314.3 — Definitions (bioavailability; bioequivalence). Electronic Code of Federal Regulations (eCFR). 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-A/section-314.3

Further reading

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $200/mo

starting dose

Get started →
7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

From $99/mo

Get started →
7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $139/mo

4-month plan rate

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →